In a report released on October 3, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Mesoblast Limited, with a price target of A$3.04. The company’s shares closed last Friday at $1.75.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shapiro covers the Healthcare sector, focusing on stocks such as Mesoblast Limited, Mayne Pharma Group, and Cogstate Ltd. According to TipRanks, Shapiro has an average return of -6.3% and a 36.31% success rate on recommended stocks.
Mesoblast Limited has an analyst consensus of Moderate Buy, with a price target consensus of $2.01.
MEOBF market cap is currently $2.34B and has a P/E ratio of -20.69.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MEOBF in relation to earlier this year.
Read More on MEOBF:
Disclaimer & DisclosureReport an Issue
- Mesoblast Reports 66% Revenue Surge for Ryoncil in Second Quarter
- Mesoblast reports Q2 Ryoncil revenue up 66% y/y
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services
- Mesoblast’s Ryoncil® Gains Medicare & Medicaid J-Code for Enhanced Access
- Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/Nvidia%20logo%20on%20phone%20screen%20with%20stock%20chart%20by%20xalien%20via%20Shutterstock.jpg)